N,N′-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors
摘要:
A series of N-(2-hydroxy-3-sulfonamidobenzene)-N'-arylcyanoguanidines was prepared. In general, these compounds proved to be potent antagonists of CXCR2 while the selectivity versus CXCR1 ranged from non-selective to > 200-fold. (c) 2006 Elsevier Ltd. All rights reserved.
This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
本发明涉及新型化合物及其组合物,用于治疗由趋化因子白细胞介素-8(IL-8)介导的疾病状态。
US7893089B2
申请人:——
公开号:US7893089B2
公开(公告)日:2011-02-22
N,N′-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors
作者:Hong Nie、Katherine L. Widdowson、Michael R. Palovich、Wei Fu、John D. Elliott、Deborah L. Bryan、Miriam Burman、Dulcie B. Schmidt、James J. Foley、Henry M. Sarau、Jakob Busch-Petersen
DOI:10.1016/j.bmcl.2006.08.042
日期:2006.11
A series of N-(2-hydroxy-3-sulfonamidobenzene)-N'-arylcyanoguanidines was prepared. In general, these compounds proved to be potent antagonists of CXCR2 while the selectivity versus CXCR1 ranged from non-selective to > 200-fold. (c) 2006 Elsevier Ltd. All rights reserved.